In addition to the low mutational burden, the most straightforward cause of the lack of responsiveness to anti-PD-1/PD-L1 is defects in the recognition of tumor cells by T cells, which can be related to the absence of tumor antigens or defects in the antigen presentation mechanism by MHC (6). This evidence concerns the gene HLA-C and neoplasm.